Ozempic® is now covered by ALL
public formularies across Canada!
Is Ozempic® right for you? Ask your doctor today to find out.
What can Ozempic® do for you?
DIN, drug identification number.
This is an official Novo Nordisk Canada Inc. website.
Ozempic® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:2
diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance
metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control
metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control
metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do not achieve adequate glycemic control
basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control
Please consult the Product Monograph at OzempicPM-E.ca or
here for more information on:
Contraindications in personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and pregnancy or breastfeeding
A serious warning on risk of thyroid C-cell tumours
Other relevant warnings and precautions relating to intramuscular administration, CV effects (increased heart rate; PR interval prolongation), hypoglycemia with concomitant use of insulin secretagogues or insulin, use with other incretin drugs, hepatic insufficiency, pancreatitis, hypersensitivity, diabetic retinopathy (in patients with history of disease, monitor for progression), and renal impairment (severe GI adverse reactions warrant monitoring of renal function; use in end-stage disease)
Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions
Quebec (RAMQ) Exceptional Medication: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated, or ineffective. Authorization is given for a weekly maximum dose of 1 mg. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient. RAMQ is an official mark of the Régie de l’assurance maladie du Québec.
* Coverage criteria: As add-on therapy for the treatment of type 2 diabetes in patients with intolerance to and/or inadequate glycemic control on: a sufficient trial (i.e., a minimum of 6 months) of metformin, AND a sulfonylurea, AND for whom insulin is not an option; OR for whom these products are contraindicated. Special authorization may be granted for 24 months. * Coverage criteria: As part of treatment for type 2 diabetes mellitus after inadequate glycemic control on maximum tolerated doses of dual therapy of metformin and a sulfonylurea or dual therapy of metformin and an insulin. Special Note: Coverage will be provided for either semaglutide or an eligible dipeptidyl peptidase-4 (DPP-4) inhibitor; for patients that have coverage for DPP-4 inhibitor, approval for semaglutide coverage will result in discontinuation of coverage for DPP-4 inhibitor; patients intolerant to a sulfonylurea may be considered for coverage. Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available through the PharmaCare Special Authority program). * Coverage criteria: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. * Coverage criteria: For the treatment of type 2 diabetes mellitus as a: second drug added to metformin for patients who have inadequate glycemic control on metformin; or third drug added to metformin and a sulfonylurea for patients who have inadequate glycemic control on metformin and a sulfonylurea. Clinical Note: For patients who cannot take metformin due to contraindications or intolerances, details must be provided. * Coverage criteria: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. * Coverage criteria: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. * Therapeutic note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control. * Therapeutic note: For the treatment of type 2 diabetes in combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control. * Therapeutic note: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. * Coverage criteria: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. * Coverage criteria: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated, or ineffective. Authorization is given for a weekly maximum dose of 1 mg. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient. * Coverage criteria: For the treatment of type 2 diabetes in combination with metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. * Coverage criteria: In addition to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea.
† Comparative clinical significance unknown. ADBL, Alberta Drug Benefit List.BC, British Columbia.NBPDP, New Brunswick Prescription Drug Program.NLPDP, Newfoundland and Labrador Prescription Drug Program.EHB, Extended Health Benefit.EHB, Extended Health Benefit.ODB, Ontario Drug Benefit.PEI, Prince Edward Island.RAMQ is an official mark of the Régie de l’assurance maladie du Québec.
The 8-digit drug identification number (DIN) is printed on the Ozempic® package
and pen. It may also be on the receipt your pharmacist gave you.
